Risk Stratification and Selection of Management Strategy for Localized Prostate Cancer
For some patients with localized prostate cancer, the treatment approach is determined by patient and disease characteristics. For others, advanced risk stratification with gene expression profiling or AI-derived digital histopathology biomarkers can help identify those who may derive greater or lesser absolute benefit from a given treatment, thus informing treatment decisions and reducing the chances of over- or under-treatment.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Acute Myeloid Leukemia: Role of FLT3 Inhibitors After Allogeneic Hematopoietic Cell Transplantation
It is important for clinicians to be aware of the emerging evidence supporting the use of FLT3 inhibitors as a predictor of post-transplant relapse in patients with AML.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00
Diagnosis and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm
Despite the rarity of blastic plasmacytoid dendritic cell neoplasm (BPDCN), it is crucial for the disease to remain in the differential diagnosis of neoplastic and non-neoplastic skin lesions and rashes, including leukemia cutis, as the disease can disseminate rapidly without therapy.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Cost $0.00
Recorded Presentation from the NCCN Pharmacy Updates: Maintenance Strategies in the Management of Acute Myeloid Leukemia
Maintenance therapy is an aspect of acute myeloid leukemia (AML) management that currently demonstrates strong promise in efforts to prolong survivability and improve overall survival. Given the forthcoming evidence in this area, it is highly important for health care professionals responsible for the care of patients with AML to be aware of both new treatment standards and emerging research in maintenance therapy options.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Cost $0.00
Review of Oral Targeted Therapies in Acute Myeloid Leukemia
In recent years, there has been an increased emphasis on molecular and genetic alterations in the classification system of acute myeloid leukemia, and, with this, an increase in the development of targeted therapies.
Category
  • Acute Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Cost $0.00